Riccardo Sacconi1,2, Livia Tomasso1, Eleonora Corbelli1, Adriano Carnevali1,3, Lea Querques1, Stefano Casati2, Francesco Bandello1, Giuseppe Querques4. 1. Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan, Italy. 2. Eye Clinic, Department of Neurological, Biomedical and Movement Sciences, University of Verona, Verona, Italy. 3. Department of Ophthalmology, University of "Magna Graecia", Catanzaro, Italy. 4. Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan, Italy. giuseppe.querques@hotmail.it.
Abstract
PURPOSE: To analyze the quantitative and qualitative early changes of choroidal neovascularization (CNV) associated with chronic central serous chorioretinopathy (CSC) after treatment using optical coherence tomography-angiography (OCT-A). METHODS: Charts of consecutive patients with diagnosis of chronic CSC complicated by CNV were retrospectively reviewed. Included patients were divided in photodynamic therapy (PDT) or aflibercept group on the basis of the treatment received (half-fluence PDT or aflibercept 2.0 mg/0.05 ml intravitreal injection). Main outcome measures included the changes between baseline and 1-month follow-up in CNV vessel density (VD) and area on OCT-A images after thresholding and binarization. RESULTS: A total of 30 eyes of 26 Caucasian patients were included: 17 eyes of 15 patients in PDT group (mean age 53 ± 11 years) and 13 eyes of 11 patients in aflibercept group (mean age 58 ± 8 years [p = 0.196]). In both PDT and aflibercept groups, best-corrected visual acuity improved at 1 month, and central macular thickness and subretinal fluid significantly decreased. VD did not change after the treatment in both groups (p = 0.502 and p = 0.086) although CNV area decreased significantly (from 0.586 ± 0.449 mm2 to 0.553 ± 0.453 mm2 [0.041]) in the PDT group, and nonsignificantly (from 0.767 ± 0.466 mm2 to 0.733 ± 0.472 mm2 [p = 0.095]) in the aflibercept group. The same results were confirmed in the subanalysis of the 18 treatment-naïve eyes. CONCLUSIONS: We demonstrated that, despite all patients showed a favorable clinical response, VD of CNVs complicating chronic CSC did not change after treatment. These findings support the idea that arteriogenesis is the main driving force of CNV in pachychoroid-related macular disorders.
PURPOSE: To analyze the quantitative and qualitative early changes of choroidal neovascularization (CNV) associated with chronic central serous chorioretinopathy (CSC) after treatment using optical coherence tomography-angiography (OCT-A). METHODS: Charts of consecutive patients with diagnosis of chronic CSC complicated by CNV were retrospectively reviewed. Included patients were divided in photodynamic therapy (PDT) or aflibercept group on the basis of the treatment received (half-fluence PDT or aflibercept 2.0 mg/0.05 ml intravitreal injection). Main outcome measures included the changes between baseline and 1-month follow-up in CNV vessel density (VD) and area on OCT-A images after thresholding and binarization. RESULTS: A total of 30 eyes of 26 Caucasian patients were included: 17 eyes of 15 patients in PDT group (mean age 53 ± 11 years) and 13 eyes of 11 patients in aflibercept group (mean age 58 ± 8 years [p = 0.196]). In both PDT and aflibercept groups, best-corrected visual acuity improved at 1 month, and central macular thickness and subretinal fluid significantly decreased. VD did not change after the treatment in both groups (p = 0.502 and p = 0.086) although CNV area decreased significantly (from 0.586 ± 0.449 mm2 to 0.553 ± 0.453 mm2 [0.041]) in the PDT group, and nonsignificantly (from 0.767 ± 0.466 mm2 to 0.733 ± 0.472 mm2 [p = 0.095]) in the aflibercept group. The same results were confirmed in the subanalysis of the 18 treatment-naïve eyes. CONCLUSIONS: We demonstrated that, despite all patients showed a favorable clinical response, VD of CNVs complicating chronic CSC did not change after treatment. These findings support the idea that arteriogenesis is the main driving force of CNV in pachychoroid-related macular disorders.
Authors: Nora W Muakkassa; Adam T Chin; Talisa de Carlo; Kendra A Klein; Caroline R Baumal; Andre J Witkin; Jay S Duker; Nadia K Waheed Journal: Retina Date: 2015-11 Impact factor: 4.256
Authors: Noel Padrón-Pérez; Luis Arias; Marcos Rubio; Daniel Lorenzo; Pere García-Bru; Jaume Català-Mora; José M Caminal Journal: Invest Ophthalmol Vis Sci Date: 2018-02-01 Impact factor: 4.799
Authors: Elon H C van Dijk; Sascha Fauser; Myrte B Breukink; Rocio Blanco-Garavito; Joannes M M Groenewoud; Jan E E Keunen; Petrus J H Peters; Greet Dijkman; Eric H Souied; Robert E MacLaren; Giuseppe Querques; Susan M Downes; Carel B Hoyng; Camiel J F Boon Journal: Ophthalmology Date: 2018-06-14 Impact factor: 12.079
Authors: Riccardo Sacconi; K Bailey Freund; Lawrence A Yannuzzi; Rosa Dolz-Marco; Eric Souied; Vittorio Capuano; Oudy Semoun; Nopasak Phasukkijwatana; David Sarraf; Adriano Carnevali; Lea Querques; Francesco Bandello; Giuseppe Querques Journal: Am J Ophthalmol Date: 2017-10-27 Impact factor: 5.258
Authors: Benedikt Schworm; Nikolaus Luft; Leonie F Keidel; Felix Hagenau; Christoph Kern; Tina Herold; Karsten U Kortuem; Siegfried G Priglinger; Jakob Siedlecki Journal: Graefes Arch Clin Exp Ophthalmol Date: 2020-02-28 Impact factor: 3.117